Renal Anemia – Epidemiology – Mature markets data
Clarivate Epidemiology’s coverage of renal anemia comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of renal anemia for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the major mature pharmaceutical markets.
Clarivate Epidemiology’s renal anemia forecast will answer the following questions:
- Of all people diagnosed with renal anemia, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of renal anemia over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MicroSoft Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 27 renal anemia patient populations, as follows:
- Stage 1 CKD with anemia (Hb less than 13 g/dl) prevalent cases
- Stage 2 CKD with anemia (Hb less than 13 g/dl) prevalent cases
- Stage 3a CKD with anemia (Hb less than 13 g/dl) prevalent cases
- Stage 3b CKD with anemia (Hb less than 13 g/dl) prevalent cases
- Stage 4 CKD with anemia (Hb less than 13 g/dl) prevalent cases
- ESRD CKD with anemia (Hb less than 13 g/dl) prevalent cases
- Nondialysis CKD cases with anemia (Hb less than 13 g/dl) prevalent cases
- Dialysis CKD cases with anemia (Hb less than 13 g/dl) prevalent cases
- Stage 1 CKD with moderate anemia (Hb 10-13 g/dl) prevalent cases
- Stage 1 CKD with severe anemia (Hb less than 10 g/dl) prevalent cases
- … and many more (details available on request).
Note: coverage may vary by country.
Table of contents
- Renal Anemia - Epidemiology - Mature markets data
- Epidemiology Data
- Methods
- Literature review (studies included in/excluded from the analyses of renal anemia
- Total prevalent cases of renal anemia by CKD stage
- Total prevalent cases of renal anemia by dialysis
- Diagnosed prevalent cases of renal anemia
- Diagnosed drug-treated prevalent cases of renal anemia
- Risk / protective factors applied to disease forecast models
- Reference Materials
Yueyao (Alex) Li, M.D., Ph.D., M.S.P.H., is an associate epidemiologist at Clarivate. Previously, she was a postdoctoral researcher at Brown University, where she worked on projects relating to skin cancer and chronic skin conditions. Dr. Li holds a medical degree specializing in general surgery from China Medical University. She also holds a Ph.D. in epidemiology from Indiana University and a master’s degree in public health from the University of South Carolina.